Daily Doxycycline for Early Syphilis
This study is looking into whether taking doxycycline 200mg once a day for 14 days is an effective treatment for early syphilis. This is different from the usual way doxycycline is given for syphilis, which is 100mg twice a day. Researchers want to see if this single daily dose works well based on how your symptoms improve and changes in your blood tests. You might be able to join if you are 18 or older and have been diagnosed with early syphilis. The study is currently unclear on its recruitment status.
- Study design
- This is an open-label study with 15 participants. All participants will receive the same treatment.
- What's involved
- You will take doxycycline 200mg daily for 14 days. You will also provide rectal and oropharyngeal (back of the mouth) samples every other day during the 14-day treatment period.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your clinical and blood test responses will be measured at 6 months after starting treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Daily Doxycycline for Early Syphillis
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Travis Hunt, MD · PRINCIPAL_INVESTIGATOR · University of Washington
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Composite clinical and serological response6 months
Clinical response and serological response will be aggregated to arrive at one reported value, a binary outcome of "yes" (1) or "no" (0). Clinical response equates to resolution of clinical symptoms of syphilis the participants presented with, such as rash or chancre, without the development of new symptoms of syphilis. Resolution will be marked as "yes" or "no". Serological response equates to a fourfold decrease in RPR compared to the presenting RPR titer by 6 months. Resolution will be marked as "yes" or "no". Thus, to generate the composite response outcome, participants with outcomes of "yes" for both clinical response and serological response will qualify as a binary outcome of "yes" (1) . Participants who do not have outcomes of "yes" for both clinical response and serological response will qualify as a binary outcome of "no" (0).